Mithridion, Inc.: Series C $1.2M

Posted in I - Series C, Q - 1Q11, R - MID WEST, X - Alzheimer's, X - CNS, X - Schizophrenia, XX - WI

Mithridion (Madison, WI) a clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia, closed a $1.2M Series C financing. Participants include, Venture Investors, the State of Wisconsin Investment Board and Rocket Venture Fund.

Jan

2011

Mind-NRG, SA: Series A $2M

Posted in I - Series A, Q - 4Q10, R - INTERNATIONAL, X - Alzheimer's, X - CNS, X - Parkinson's, X - Schizophrenia

Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing. Participants include Index Ventures.

Dec

2008

Sierra Neuropharmaceuticals: Series A $21.5M

Posted in I - Series A, Q - 3Q08, R - ROCKY MOUNTAIN, X - Epilepsy, X - Neurology, X - Schizophrenia

Sierra Neuropharmaceuticals (Aurora, CO) development-stage biopharmaceutical company specializing treating neurological disorders, closed a $21.5M Series A financing. Participants include HealthCare Ventures, Morgenthaler Ventures, Sequel Ventures and High Country Venture.

Nov

2008

Concert Pharmaceuticals, Inc.: Series C $37.0M

Posted in I - Series C, Q - 2Q08, R - NORTH EAST, X - HIV, X - MRSA, X - Pain, X - Schizophrenia

Concert Pharmaceuticals (Lexington, MA) development-stage pharmaceutical company focused on new chemical entities based upon modifications of validated drug molecules using deuterium chemistry, closed a $37M Series C financing. Participants include Adage Capital Management, SR One, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, Flagship Ventures, [...]

Feb

2008

Genizon Biosciences, Inc.: Series D $31M

Posted in I - Series D, Q - 1Q08, R - INTERNATIONAL, X - Asthma, X - Biomarker, X - Crohn's, X - Schizophrenia

Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.

to top of page...